Atomo Diagnostics Limited (ASX:AT1)

Market Cap	33.22M
Revenue (ttm)	3.79M
Net Income (ttm)	-4.97M
Shares Out	810.18M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,919,761
Average Volume	1,132,622
Open	0.0370
Previous Close	0.0360
Day's Range	0.0370 - 0.0440
52-Week Range	0.0140 - 0.0430
Beta	1.16
RSI	50.61
Earnings Date	Jan 27, 2026

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In 2025, Atomo Diagnostics's revenue was 3.79 million, a decrease of -7.20% compared to the previous year's 4.09 million. Losses were -4.97 million, -27.41% less than in 2024.